<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997659</url>
  </required_header>
  <id_info>
    <org_study_id>2007-5689</org_study_id>
    <nct_id>NCT00997659</nct_id>
  </id_info>
  <brief_title>Chromium's Effect on Insulin Resistance in Obesity</brief_title>
  <official_title>Efficacy and Safety of Chromium as a Therapeutic Intervention for Insulin Resistance Associated With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is to investigate the nutritional supplement chromium picolinate. A large&#xD;
      number of people use chromium picolinate from health food stores to improve the function of&#xD;
      the hormone insulin. The investigators are testing how effective this supplement is and are&#xD;
      also monitoring its safety. In patients with diabetes, chromium has been shown to increase&#xD;
      sensitivity to the hormone insulin. Since obesity can cause insensitivity or resistance to&#xD;
      insulin, the investigators are studying obese individuals with documented insulin resistance.&#xD;
      The investigators would like to know if chromium is also effective in treating the insulin&#xD;
      resistance associated with obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure used for sample size evaluations is the (before and after) change in the rate of glucose disposal during infusion of insulin (Rd, in mg of glucose/kg lean body mass/minute)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>chromium picolinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>chromium picolinate</intervention_name>
    <description>1000 mg per day</description>
    <arm_group_label>chromium picolinate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age &gt; 18 years;&#xD;
&#xD;
          2. a BMI greater or equal to 30; AND&#xD;
&#xD;
          3. an abnormal 2 hour postprandial glucose (greater than 140 mg/dl but less than 200&#xD;
             mg/dl) following 75 grams of a glucose load.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. positive pregnancy test (all women must have a negative pregnancy test before&#xD;
             beginning protocol);&#xD;
&#xD;
          2. diagnosis of cancer;&#xD;
&#xD;
          3. acute illness of any sort, however, patients may be enrolled once they are stable;&#xD;
&#xD;
          4. hemoglobin less than 11.0 g/dl or hemodynamically unstable;&#xD;
&#xD;
          5. creatinine greater than or equal to 1.5 mg/dl;&#xD;
&#xD;
          6. liver dysfunction as evidenced by elevations in transaminases 2-fold higher than upper&#xD;
             limit of normal;&#xD;
&#xD;
          7. use of certain medications within the past month (e.g., glucocorticoids).&#xD;
&#xD;
          8. untreated hypertension (systolic BP &gt; 150 mmHG, diastolic BP&gt;IOO mmHG);&#xD;
&#xD;
          9. patients with diabetes mellitus;&#xD;
&#xD;
         10. hypogonadism;&#xD;
&#xD;
         11. abnormal thyroid function (serum T4 &lt; 4 or &gt; 12; TSH &lt; 0.35 or &gt; 5.5) (12) any chronic&#xD;
             liver or kidney disease; OR&#xD;
&#xD;
         12. polycystic ovarian syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stony Brook University GCRC</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>August 11, 2011</last_update_submitted>
  <last_update_submitted_qc>August 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dennis Mynarcik, PhD</name_title>
    <organization>Stony Brook University</organization>
  </responsible_party>
  <keyword>chromium picolinate</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Picolinic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

